Moderna CEO Updates Schedule of COVID-19 Vaccine Trial Results

0
37


Moderna, the first pharmaceutical company to conduct human trials of a coronavirus vaccine in the United States, said it should know in November whether its vaccine is working. Moderna CEO Stephane Bancel told CNBC on Thursday that he may have enough data by October on his advanced trial to assess its effectiveness, although he said he considered the timeline unlikely. , according to the report.





© Credit: CBSNews
cbsn-fusion-modernas-coronavirus-vaccin-triggers-immun-response-known-safe-to-move-to-phase-3-testing-thumbnail-514776-640×360.jpg


President Donald Trump said a vaccine could be ready ” during the month of October“Experts believe this is unlikely given the time required to test and evaluate vaccines for efficacy and safety. United States Centers for Disease Control director Robert Redfield told Congress on Wednesday that a vaccine would not be widely available until the second or third quarter of next year – a projection with which Mr Trump took issue, saying Redfield “made a mistake.”

President of Moderna on transparency in vaccine development

Click to enlarge

FOLLOWING

FOLLOWING

Redfield also said that a mask might be even more effective at fighting the virus than a vaccine for someone who fails to create an immune response from the vaccine.

“This face mask is safer to protect me from COVID than when I take a COVID vaccine,” Redfield said, pointing to his mask. “… If I don’t get an immune response, the vaccine won’t protect me. This face mask will. ”

So far, seven vaccines, including Moderna’s product, are in final testing phase 3, which involves large-scale testing on people.

“If the infection rate in the country were to slow in the coming weeks, it could potentially be pushed back in the worst case to December,” Bancel told CNBC.


woman wearing blue shirt: final clinical trials of COVID-19 vaccines 3:20


© Provided by CBS News
COVID-19 Vaccine Final Clinical Trials 3:20 AM


In a presentation Thursday about Moderna’s research and development efforts, the company said it had recruited more than 25,000 people into the Phase 3 trial. The company announced promising results in a test on a smaller scale earlier this year.

The company also said it was scaling manufacturing to produce between 500 million and 1 billion doses of the vaccine.

Moderna’s vaccine, which uses messenger RNA, or mRNA, to trick the body into making viral proteins to fight disease, might require two injections to provide protection against the coronavirus. About 10,000 volunteers received a second injection in the Phase 3 trial, Moderna said Thursday.

However, no mRNA vaccine has so far been approved for an infectious disease, and Moderna has yet to bring a product to market, analysts at Deutsche Bank say.

Continue reading

LEAVE A REPLY

Please enter your comment!
Please enter your name here